On November 10, 2021 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, reported that Dr. Elizabeth Evans, PhD, Chief Operating Officer and SVP, Discovery and Translational Medicine, reported that it will present Poster #434, Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84), at the Society for Immunology of Cancer’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting being held from November 12th – 14th in Washington D.C (Press release, Vaccinex, NOV 10, 2021, View Source [SID1234595057]). Please see Presentation details below:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SITC Conference Information
Date: November 12-14, 2021
Session Title: Clinical Trials in Progress, Poster Session
Poster #: Title Poster #434: Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)
Add to calendar: View Source
Program Link: View Source
Access: The Poster will be presented in-person 12:30 -2 and 7 – 8:30 p.m. ET on Saturday, November 13, and on the SITC (Free SITC Whitepaper) 2021 virtual meeting platform from 7 a.m. ET on Friday, November 12, 2021, until the virtual meeting platform is closed on January 9, 2022. The Poster will also be available on Vaccinex’s website starting on November 12, 2021, at: View Source
For more information about the SITC (Free SITC Whitepaper) Annual Meeting please refer to the conference website. The in-person program in Washington D.C. will be streamed live on the digital platform.